AstraZeneca presented the full Phase 3 Bax24 data for baxdrostat at the American Heart Association Scientific Sessions on November 11, 2025. The oral aldosterone synthase inhibitor met its primary endpoint, showing a 14.0 mmHg reduction in ambulatory 24‑hour systolic blood pressure versus placebo, a statistically significant improvement that exceeds the 10 mmHg threshold typically considered clinically meaningful.
Secondary endpoints also demonstrated clinically relevant benefits: nighttime systolic pressure fell 13.9 mmHg and seated systolic pressure dropped 10.3 mmHg compared with placebo. The safety profile was favorable, with no new safety signals reported across the study population.
Baxdrostat addresses a substantial unmet need in treatment‑resistant hypertension, a condition affecting roughly 700 million people worldwide. AstraZeneca estimates an addressable U.S. market of more than 200 million patients, positioning the drug as a potential $5 billion‑plus asset once approved.
The company acquired the drug in February 2023 for $1.8 billion, including contingent value payments, and has since advanced it through Phase 3. The positive results reinforce AstraZeneca’s strategy to broaden its cardiovascular portfolio and diversify beyond its core oncology and rare‑disease businesses.
Executive Vice President Sharon Barr highlighted the drug’s impact: “The Bax24 data demonstrate the significant effect that baxdrostat’s long half‑life and highly selective inhibition of aldosterone synthase can have in improving 24‑hour and overnight blood pressure for patients with resistant hypertension.”
Baxdrostat’s once‑daily oral dosing and lack of food restrictions make it a convenient alternative to current injectable or multi‑tablet regimens, potentially improving adherence and patient outcomes. The trial’s success strengthens AstraZeneca’s pipeline and supports its broader growth ambitions in cardiovascular medicine.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.